Attivo Networks Press Release

BD Tag

Attivo Networks

Marshall Heilman, Chris Roberts, Lawrence Pingree, and Bill Ender Join Attivo Networks® Advisory Board

Reading Time: 3 minutes  |  Published: August 2, 2018 in Press Release
0 Comments

New Advisory Board Members Bring Deep Knowledge of Information Security, Incident Response, Counterintelligence, and Pen Testing Expertise to Foster Continued Deception Technology Innovation. Attivo Networks announced today that four widely acknowledged cybersecurity industry experts, Marshall Heilman, Chris Roberts, Lawrence Pingree, and Bill Ender have joined the...

Urgent Care: Deception-Based Detection Stat!

Reading Time: 3 minutes  |  Published: February 22, 2018 in Blogs, Healthcare
0 Comments

By: Christina Adams  Healthcare organizations work hard to ensure their patients’ care and their sensitive data remain protected. Those working within the healthcare sector know the importance of optimizing care for their patients through the use of high-tech, state of the art medical devices and online...

BioWorld MedTech Logo

BD and Attivo Partner to Thwart Cyberattacks

Reading Time: < 1 minute  |  Published: February 15, 2018 in Attivo News
0 Comments

As medical devices incorporate connectivity, they provide greater opportunities for convenience, service, and information for consumers and companies, but also are increasingly vulnerable to cyber threats. In this environment, Attivo Networks and Becton, Dickinson and Co. (BD) have validated a deception solution for medical technology...

Attivo Networks® Receives Validation for Attivo BOTsink® Deception-Based Threat Detection through BD Product Security Partnership Program

Reading Time: 3 minutes  |  Published: February 14, 2018 in Press Release
0 Comments

“We welcome Attivo Networks to the BD Product Security Partnership Program as an important collaborator in our collective quest to improve cybersecurity across the health care industry,” said Rob Suarez, director of Product Security for BD.  “The Attivo BOTsink solution was rigorously tested and validated...